The area of fixation covaries with short-term changes in visual acuity after anti-vascular endothelial growth factor treatment in patients with diabetic macular oedema

Autor: Toke Bek, Dorte Ancher Larsen, Nanna Stæhr Jakobsen
Rok vydání: 2018
Předmět:
Vascular Endothelial Growth Factor A
Male
Visual acuity
genetic structures
Visual Acuity/physiology
Visual Acuity
Angiogenesis Inhibitors
Bevacizumab/therapeutic use
chemistry.chemical_compound
0302 clinical medicine
Prospective Studies
Anti vegf
Macular Edema/drug therapy
General Medicine
Diabetic retinopathy
Middle Aged
Fixation
Ocular/physiology
Bevacizumab
Saccades/physiology
Vascular endothelial growth factor
Intravitreal Injections
Diabetic Retinopathy/drug therapy
Female
medicine.symptom
medicine.medical_specialty
Fixation
Ocular
Macular Edema
Ranibizumab/therapeutic use
03 medical and health sciences
Ranibizumab
Ophthalmology
Saccades
medicine
Humans
Vascular Endothelial Growth Factor A/antagonists & inhibitors
In patient
Angiogenesis Inhibitors/therapeutic use
Diabetic Retinopathy
business.industry
Retinal
medicine.disease
Diabetic macular oedema
chemistry
Fixation (visual)
030221 ophthalmology & optometry
sense organs
business
030217 neurology & neurosurgery
Follow-Up Studies
Zdroj: Jakobsen, N S, Larsen, D A & Bek, T 2018, ' The area of fixation covaries with short-term changes in visual acuity after anti-vascular endothelial growth factor treatment in patients with diabetic macular oedema ', Acta Ophthalmologica, vol. 96, no. 7, pp. 744-748 . https://doi.org/10.1111/aos.13773
ISSN: 1755-375X
DOI: 10.1111/aos.13773
Popis: PURPOSE: Diabetic maculopathy can be treated with intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors. However, the therapy is not effective in all patients, and it would be desirable to have parameters for differentiating patients who will benefit from treatment from those who will not. Retinal fixation has been shown to be impaired in patients with low visual acuity (VA) secondary to macular disease, but the changes in fixational eye movements after anti-VEGF treatment for diabetic maculopathy have not been investigated.METHODS: Retinal fixation was studied in 29 patients with diabetic macular oedema before three monthly anti-VEGF injections, and 1 and 4 months after the last injection. The change in VA was correlated with changes in area, frequency, amplitude and total number of fixational saccades.RESULTS: During three monthly injections, best-corrected visual acuity (BCVA) increased from (mean ± SD) 74.0 ± 11.5 Early Treatment Diabetic Retinopathy Study (ETDRS) letters to 78.3 ± 9.8 ETDRS letters, (p = 0.003) and central retinal thickness (CRT) decreased from (mean ± SD) 441.7 ± 107.0 μm to 339.5 ± 74.2 μm, (p = CONCLUSION: Fixational eye movements may be used to monitor short-term effects of anti-VEGF treatment on diabetic macular oedema. Future studies should aim at investigating a possible predictive value of fixational eye movements for visual function in the long term.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje